{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:41:12Z","timestamp":1781894472434,"version":"3.54.5"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["NS-50895"],"award-info":[{"award-number":["NS-50895"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AG-20241"],"award-info":[{"award-number":["AG-20241"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["IIRG-12-239626"],"award-info":[{"award-number":["IIRG-12-239626"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["NIRG-13-281227"],"award-info":[{"award-number":["NIRG-13-281227"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of California Alzheimer\u2019s Disease Research Center"},{"name":"NIH\/NIA","award":["P50 AG16573"],"award-info":[{"award-number":["P50 AG16573"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ymthe.2016.10.002","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T21:45:39Z","timestamp":1483652739000},"page":"153-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of \u03b2-Amyloid in an Animal Model of Alzheimer\u2019s Disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Irina","family":"Petrushina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayk","family":"Davtyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Hovakimyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpine","family":"Davtyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle F.","family":"Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Cribbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Agadjanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2016.10.002_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2016.10.002_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2016.10.002_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2015.04.005","article-title":"ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of \u03b2-amyloid peptide in hippocampal neurons","volume":"100","author":"S\u00e1ez-Orellana","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ymthe.2016.10.002_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/156720508784533321","article-title":"Structure-function implications in Alzheimer\u2019s disease: effect of Abeta oligomers at central synapses","volume":"5","author":"Cerpa","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ymthe.2016.10.002_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1101\/cshperspect.a006296","article-title":"The genetics of Alzheimer disease","volume":"2","author":"Tanzi","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2016.10.002_bib7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2016.10.002_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1471-4159.2006.04443.x","article-title":"The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase","volume":"101","author":"Sahlin","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.10.002_bib10","doi-asserted-by":"crossref","first-page":"30990","DOI":"10.1074\/jbc.M114.589069","article-title":"Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein","volume":"289","author":"Maloney","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/acschemneuro.5b00171","article-title":"Amyloid \u03b2-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer\u2019s Disease Mutation","volume":"6","author":"Zheng","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ymthe.2016.10.002_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.celrep.2014.09.037","article-title":"Sorting nexin 27 regulates A\u03b2 production through modulating \u03b3-secretase activity","volume":"9","author":"Wang","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2016.10.002_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1091\/mbc.e09-10-0850","article-title":"Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP","volume":"21","author":"Granic","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ymthe.2016.10.002_bib14","first-page":"1192","article-title":"Review and hypothesis: Alzheimer disease and Down syndrome--chromosome 21 nondisjunction may underlie both disorders","volume":"48","author":"Potter","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2016.10.002_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2016.10.002_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1326-9-51","article-title":"Models of \u03b2-amyloid induced Tau-pathology: the long and \u201cfolded\u201d road to understand the mechanism","volume":"9","author":"Stancu","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2016.10.002_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib19","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","article-title":"Disaggregation of Alzheimer beta-amyloid by site-directed mAb","volume":"94","author":"Solomon","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2016.10.002_bib20","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.297.5585.1260","article-title":"New therapies. New Alzheimer\u2019s treatments that may ease the mind","volume":"297","author":"Helmuth","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2016.10.002_bib21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm1234","article-title":"Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in\u00a0vivo","volume":"11","author":"Klyubin","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2016.10.002_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2125.2011.04134.x","article-title":"New pharmacological strategies for treatment of Alzheimer\u2019s disease: focus on disease modifying drugs","volume":"73","author":"Salomone","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.ymthe.2016.10.002_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-2011-110182","article-title":"Targeting oligomers in neurodegenerative disorders: lessons from \u03b1-synuclein, tau, and amyloid-\u03b2 peptide","volume":"24","author":"Gadad","year":"2011","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ymthe.2016.10.002_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","article-title":"Amyloid-based immunotherapy for Alzheimer\u2019s disease in the time of prevention trials: the way forward","volume":"10","author":"Panza","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2016.10.002_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","article-title":"\u2018Clinical trials in Alzheimer\u2019s disease\u2019: immunotherapy approaches","volume":"120","author":"Delrieu","year":"2012","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib27","first-page":"628070","article-title":"Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer\u2019s disease","volume":"2012","author":"Lobello","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.ymthe.2016.10.002_bib28","unstructured":"Ghochikyan, A., and Agadjanyan, M.G. (2012). CAD-106, a beta-amyloid-based immunotherapeutic for Alzheimer\u2019s disease. Thompson Reuter. https:\/\/partnering.thomson-pharma.com."},{"key":"10.1016\/j.ymthe.2016.10.002_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152709787847270","article-title":"Active and passive Abeta-immunotherapy: pre-clinical and clinical studies and future directions: part II","volume":"8","author":"Cribbs","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.ymthe.2016.10.002_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/187152709787847289","article-title":"AD vaccines: conclusions and future directions","volume":"8","author":"Wisniewski","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ymthe.2016.10.002_bib31","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","article-title":"A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer\u2019s disease","volume":"11","author":"Agadjanyan","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2016.10.002_bib32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2016.10.002_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","article-title":"Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer\u2019s disease","volume":"14","author":"Ferrer","year":"2004","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","article-title":"Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease","volume":"64","author":"Masliah","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2016.10.002_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/187152709787847298","article-title":"Rationale for peptide and DNA based epitope vaccines for Alzheimer\u2019s disease immunotherapy","volume":"8","author":"Ghochikyan","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ymthe.2016.10.002_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2016.10.002_bib37","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4049\/jimmunol.174.3.1580","article-title":"Prototype Alzheimer\u2019s disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T\u00a0cell epitope pan HLA DR-binding peptide","volume":"174","author":"Agadjanyan","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid","volume":"15","author":"Cribbs","year":"2003","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(02)01357-5","article-title":"Importance of IgG2c isotype in the immune response to b-amyloid in APP\/Tg mice","volume":"338","author":"Petrushina","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2016.10.002_bib40","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2016.10.002_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2014.01.002","article-title":"Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer\u2019s disease vaccines","volume":"268","author":"Davtyan","year":"2014","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib42","doi-asserted-by":"crossref","first-page":"e2124","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2016.10.002_bib43","doi-asserted-by":"crossref","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","article-title":"Alzheimer\u2019s disease peptide epitope vaccine reduces insoluble but not soluble\/oligomeric Abeta species in amyloid precursor protein transgenic mice","volume":"27","author":"Petrushina","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2016.10.002_bib44","doi-asserted-by":"crossref","first-page":"795375","DOI":"10.1155\/2014\/795375","article-title":"Amyloid beta: multiple mechanisms of toxicity and only some protective effects?","volume":"2014","author":"Carrillo-Mora","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ymthe.2016.10.002_bib45","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","article-title":"Alzheimer\u2019s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers","volume":"29","author":"De Felice","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2016.10.002_bib46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-beta protein assembly in the brain impairs memory","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.10.002_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2016.10.002_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-2094-1-24","article-title":"Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage","volume":"1","author":"Wilcock","year":"2004","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2016.10.002_bib49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/187152709787847324","article-title":"Critical issues for successful immunotherapy in Alzheimer\u2019s disease: development of biomarkers and methods for early detection and intervention","volume":"8","author":"Tarawneh","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ymthe.2016.10.002_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/187152709787847315","article-title":"Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial","volume":"8","author":"Kokjohn","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ymthe.2016.10.002_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2016.10.002_bib52","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1096\/fj.06-7685com","article-title":"Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model","volume":"21","author":"Mouri","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2016.10.002_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.nlm.2007.09.008","article-title":"Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation for cognitive performance of mid-aged mice","volume":"89","author":"Frye","year":"2008","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2014.08.002","article-title":"Assessing rodent hippocampal involvement in the novel object recognition task. A review","volume":"285","author":"Cohen","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ymthe.2016.10.002_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1101\/lm.026070.112","article-title":"Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer\u2019s disease","volume":"19","author":"Guzm\u00e1n-Ramos","year":"2012","journal-title":"Learn. Mem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib56","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1101\/lm.1028008","article-title":"The consolidation of object and context recognition memory involve different regions of the temporal lobe","volume":"15","author":"Balderas","year":"2008","journal-title":"Learn. Mem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib57","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.neubiorev.2007.01.005","article-title":"The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents","volume":"31","author":"Dere","year":"2007","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ymthe.2016.10.002_bib58","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2016.10.002_bib59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.10.002_bib60","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.10.002_bib61","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.10.002_bib62","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","article-title":"Immunotherapy for Alzheimer\u2019s disease","volume":"88","author":"Wisniewski","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2016.10.002_bib63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12168","article-title":"Amyloid-\u00df-directed immunotherapy for Alzheimer\u2019s disease","volume":"275","author":"Lannfelt","year":"2014","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ymthe.2016.10.002_bib64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Gody\u0144","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ymthe.2016.10.002_bib65","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.vaccine.2005.11.039","article-title":"Prototype Alzheimer\u2019s disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch","volume":"24","author":"Ghochikyan","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2016.10.002_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/gt.2009.140","article-title":"DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice","volume":"17","author":"Davtyan","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2016.10.002_bib67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jalz.2013.04.505","article-title":"Epitope-based DNA vaccine for Alzheimer\u2019s disease: translational study in macaques","volume":"10","author":"Evans","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2016.10.002_bib68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","article-title":"The MultiTEP platform-based Alzheimer\u2019s disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates","volume":"10","author":"Davtyan","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2016.10.002_bib69","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","article-title":"Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease","volume":"21","author":"Kawarabayashi","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2016.10.002_bib70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.10.002_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuint.2006.03.019","article-title":"Novel approaches for immunotherapeutic intervention in Alzheimer\u2019s disease","volume":"49","author":"Vasilevko","year":"2006","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ymthe.2016.10.002_bib72","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer\u2019s disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2016.10.002_bib73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1471-4159.2002.00889.x","article-title":"Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer\u2019s disease","volume":"81","author":"DeMattos","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib74","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2016.10.002_bib75","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0169-409X(02)00158-8","article-title":"Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer\u2019s disease","volume":"54","author":"Holtzman","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2016.10.002_bib76","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","article-title":"Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier","volume":"106","author":"Shibata","year":"2000","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2016.10.002_bib77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1471-4159.2004.02385.x","article-title":"Clearing amyloid through the blood-brain barrier","volume":"89","author":"Zlokovic","year":"2004","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2016.10.002_bib78","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuron.2004.07.017","article-title":"LRP\/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms","volume":"43","author":"Deane","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2016.10.002_bib79","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0197-4580(01)00245-7","article-title":"Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition","volume":"22","author":"Das","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2016.10.002_bib80","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1742-2094-2-28","article-title":"Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer\u2019s disease","volume":"2","author":"Zhou","year":"2005","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2016.10.002_bib81","doi-asserted-by":"crossref","first-page":"11495","DOI":"10.1523\/JNEUROSCI.3697-05.2005","article-title":"IgG-assisted age-dependent clearance of Alzheimer\u2019s amyloid beta peptide by the blood-brain barrier neonatal Fc receptor","volume":"25","author":"Deane","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2016.10.002_bib82","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ajpath.2013.01.021","article-title":"The bradykinin B1 receptor regulates A\u03b2 deposition and neuroinflammation in Tg-SwDI mice","volume":"182","author":"Passos","year":"2013","journal-title":"Am. J. Pathol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616453499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616453499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T03:30:46Z","timestamp":1657683046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616453499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1525001616453499"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.002","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of \u03b2-Amyloid in an Animal Model of Alzheimer\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}